Prime Medicine Shares up 15% Premarket on License Agreement With Bristol Myers Squibb for T-Cell Therapies
Prime Medicine的股價在盤前上漲15%,與百特製藥公司就t細胞療法達成許可協議
Prime Medicine Shares up 15% Premarket on License Agreement With Bristol Myers Squibb for T-Cell Therapies
Prime Medicine的股價在盤前上漲15%,與百特製藥公司就t細胞療法達成許可協議
譯文內容由第三人軟體翻譯。